Nov 8 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO executives, speaking on a conference call:
* Valeant Pharmaceuticals repaid $1.61 billion permanent debt year to date by Nov. 8; will pay $1.7 billion in 2016
* CFO expects 2017 revenue, adjusted EBITDA to be down from 2016
* CFO says company should keep core assets, but not at all cost
* CFO says company has addressed most 'unknowns' but could be more surprises ahead Further company coverage: VRX.TO